James D. Vasta
James D. Vasta has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Brian Robers
Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA
3 shared publications - Kilian V. M. Huber
Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
2 shared publications - Michael T. Beck
Promega
2 shared publications - Ani Michaud
Promega Corporation
1 shared publication - Ani Michaud
Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53719, USA
1 shared publication - Benedict-Tilman Berger
Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue-Straße 15, Frankfurt am Main, Germany, 60438
1 shared publication
Latest Publications
- Open Access
- 6 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
A Live Cell BRET Probe to Quantify PRMT5-MTA Uncompetitive Target Engagement
The PRMT5 methyltransferase plays a global role in cell physiology and is an established therapeutic target in cancer. In 10% of human cancers, deletion of the MTAP gene results in accumulation of MTA, exposing a synthetic lethality and opportunity for precision medicine by selective targeting of PRMT5 in this context. Reported small molecule PRMT5 inhibitors engage either cosubstrate (SAM) or peptide-substrate pockets through diverse mechanisms. A subset of chemotypes demonstrate uncompetitive engagement with SAM or its inhibitory metabolic precursor, MTA. Here we describe the development of a cell-permeable BRET probe CBH-002 that acts as a dynamic biosensor of the intracellular SAM/MTA pool. Using this probe, we evaluate a range of diverse PRMT5 inhibitors to mechanistically characterize and quantify uncompetitive target engagement and ternary complex formation at PRMT5-SAM and -MTA complexes in live cells, enabling direct insights into drug mechanism-of-action and metabolite-dependent response to inhibitors.
- 6 January 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Live Cell BRET Probe to Quantify PRMT5-MTA Uncompetitive Target Engagement
The PRMT5 methyltransferase plays a global role in cell physiology and is an established therapeutic target in cancer. In 10% of human cancers, deletion of the MTAP gene results in accumulation of MTA, exposing a synthetic lethality and opportunity for precision medicine by selective targeting of PRMT5 in this context. Reported small molecule PRMT5 inhibitors engage either cosubstrate (SAM) or peptide-substrate pockets through diverse mechanisms. A subset of chemotypes demonstrate uncompetitive engagement with SAM or its inhibitory metabolic precursor, MTA. Here we describe the development of a cell-permeable BRET probe CBH-002 that acts as a dynamic biosensor of the intracellular SAM/MTA pool. Using this probe, we evaluate a range of diverse PRMT5 inhibitors to mechanistically characterize and quantify uncompetitive target engagement and ternary complex formation at PRMT5-SAM and -MTA complexes in live cells, enabling direct insights into drug mechanism-of-action and metabolite-dependent response to inhibitors.
- Open Access
Development of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells
PLK1 is a protein kinase that regulates mitosis and is both an important oncology drug target and a potential antitarget of drugs for the DNA damage response pathway or anti-infective host kinases. To expand the range of live cell NanoBRET target engagement assays to include PLK1, we developed an energy transfer probe based on the anilino-tetrahydropteridine chemotype found in several selective PLK inhibitors. Probe 11 was used to configure NanoBRET target engagement assays for PLK1, PLK2, and PLK3 and measure the potency of several known PLK inhibitors. In-cell target engagement for PLK1 was in good agreement with the reported cellular potency for the inhibition of cell proliferation. Probe 11 enabled the investigation of the promiscuity of adavosertib, which had been described as a dual PLK1/WEE1 inhibitor in biochemical assays. Live cell target engagement analysis of adavosertib via NanoBRET demonstrated PLK activity at micromolar concentrations but only selective engagement of WEE1 at clinically relevant doses.
Open AccessDevelopment of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells
PLK1 is a protein kinase that regulates mitosis and is both an important oncology drug target and a potential antitarget of drugs for the DNA damage response pathway or anti-infective host kinases. To expand the range of live cell NanoBRET target engagement assays to include PLK1, we developed an energy transfer probe based on the anilino-tetrahydropteridine chemotype found in several selective PLK inhibitors. Probe 11 was used to configure NanoBRET target engagement assays for PLK1, PLK2, and PLK3 and measure the potency of several known PLK inhibitors. In-cell target engagement for PLK1 was in good agreement with the reported cellular potency for the inhibition of cell proliferation. Probe 11 enabled the investigation of the promiscuity of adavosertib, which had been described as a dual PLK1/WEE1 inhibitor in biochemical assays. Live cell target engagement analysis of adavosertib via NanoBRET demonstrated PLK activity at micromolar concentrations but only selective engagement of WEE1 at clinically relevant doses.
- 26 August 2021
- Published by Springer Nature
- Vol. 2365, 265-282
A High-Throughput Method to Prioritize PROTAC Intracellular Target Engagement and Cell Permeability Using NanoBRET
Target engagement and cell permeation are important parameters that may limit the efficacy of proteolysis-targeting chimeras (PROTACs). Here, we present an approach that facilitates both the quantitation of PROTAC binding affinity for an E3 ligase of interest, as well as the assessment of relative intracellular availability. We present a panel of E3 ligase target engagement assays based upon the NanoBRET Target Engagement platform. Querying E3 ligase engagement under live-cell and permeabilized-cell conditions allow calculation of an availability index that can be used to rank order the intracellular availability of PROTACs. Here we present examples where the cellular availability of PROTACs and their monovalent precursors are prioritized using NanoBRET assays for CRBN or VHL E3 ligases.
- 26 August 2021
- Published by Springer Nature
- Vol. 2365, 265-282
A High-Throughput Method to Prioritize PROTAC Intracellular Target Engagement and Cell Permeability Using NanoBRET
Target engagement and cell permeation are important parameters that may limit the efficacy of proteolysis-targeting chimeras (PROTACs). Here, we present an approach that facilitates both the quantitation of PROTAC binding affinity for an E3 ligase of interest, as well as the assessment of relative intracellular availability. We present a panel of E3 ligase target engagement assays based upon the NanoBRET Target Engagement platform. Querying E3 ligase engagement under live-cell and permeabilized-cell conditions allow calculation of an availability index that can be used to rank order the intracellular availability of PROTACs. Here we present examples where the cellular availability of PROTACs and their monovalent precursors are prioritized using NanoBRET assays for CRBN or VHL E3 ligases.
- 20 June 2020
- Published by Annual Reviews in Annual Review of Biochemistry
- Vol. 89 (1) , 557-581
Quantifying Target Occupancy of Small Molecules Within Living Cells
The binding affinity and kinetics of target engagement are fundamental to establishing structure–activity relationships (SARs) for prospective therapeutic agents. Enhancing these binding parameters for operative targets, while minimizing binding to off-target sites, can translate to improved drug efficacy and a widened therapeutic window. Compound activity is typically assessed through modulation of an observed phenotype in cultured cells. Quantifying the corresponding binding properties under common cellular conditions can provide more meaningful interpretation of the cellular SAR analysis. Consequently, methods for assessing drug binding in living cells have advanced and are now integral to medicinal chemistry workflows. In this review, we survey key technological advancements that support quantitative assessments of target occupancy in cultured cells, emphasizing generalizable methodologies able to deliver analytical precision that heretofore required reductionist biochemical approaches.
- 20 June 2020
- Published by Annual Reviews in Annual Review of Biochemistry
- Vol. 89 (1) , 557-581
Quantifying Target Occupancy of Small Molecules Within Living Cells
The binding affinity and kinetics of target engagement are fundamental to establishing structure–activity relationships (SARs) for prospective therapeutic agents. Enhancing these binding parameters for operative targets, while minimizing binding to off-target sites, can translate to improved drug efficacy and a widened therapeutic window. Compound activity is typically assessed through modulation of an observed phenotype in cultured cells. Quantifying the corresponding binding properties under common cellular conditions can provide more meaningful interpretation of the cellular SAR analysis. Consequently, methods for assessing drug binding in living cells have advanced and are now integral to medicinal chemistry workflows. In this review, we survey key technological advancements that support quantitative assessments of target occupancy in cultured cells, emphasizing generalizable methodologies able to deliver analytical precision that heretofore required reductionist biochemical approaches.